-+ 0.00%
-+ 0.00%
-+ 0.00%

Kiora starts Phase 2 ABACUS-2 trial of KIO-301 in retinitis pigmentosa

PUBT·04/14/2026 11:08:45
Listen to the news
Kiora starts Phase 2 ABACUS-2 trial of KIO-301 in retinitis pigmentosa
  • Kiora published Phase 1 ABACUS-1 results for KIO-301 in late-stage retinitis pigmentosa in Nature Medicine.
  • Results were already presented via publication, showing short-term safety with no serious treatment-related issues reported.
  • Exploratory assessments showed variable signals of light responsiveness in some participants, with patient-reported quality-of-life measures improving over the study period.
  • Company has started ABACUS-2, a randomized controlled Phase 2 trial designed to test higher doses while comparing functional vision outcomes against a control group.
  • Control-group participants are slated to become eligible for KIO-301 in an open-label extension, supporting a broader data package for potential development decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202604140700NEWSFILECNPR____20260414_292220_1) on April 14, 2026, and is solely responsible for the information contained therein.